Singapore, July 28 -- Co-Diagnostics, Inc., a US-based molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, has announced that CoSara Diagnostics, the company's joint venture in India, has sent test kits of the SARAGENE(R) Bundibugyo Virus Test to a third-party laboratory for evaluation following a request by the Centre for Cellular and Molecular Platforms (C-CAMP), an initiative supported by the Department of Biotechnology, Government of India.

The company has also announced successful completion of a proof-of-concept study evaluating an extraction-free Co-Primers(R) Ebola test on the Co-Dx PCR Pro(R) instrument using diluted plasma as a sample type. This feasibility work repr...